Please login to the form below

Not currently logged in

Shire acts against Sandoz and Amneal

Shire is taking legal action against Amneal and Sandoz for patent infringements

Shire has filed lawsuits in the US District Court for the District of New Jersey against each of Amneal Pharmaceuticals and Sandoz for infringement of Shire's VYVANSE patents.

The lawsuits were initiated in response to abbreviated new drug applications filed by Amneal and Sandoz seeking US Food and Drug Administration (FDA) approval to market and sell generic versions of all currently approved doses of VYVANSE.

Under the Hatch-Waxman Act, the FDA must refrain from approving the Sandoz and Amneal ANDAs for 30 months (expiring August 23, 2014), or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.

Sandoz declined to comment, while Amneal was unavailable to comment at the time of writing.

4th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....